Fundraising FoxGlobal BioAccess Fund — Full Portfolio
12 tracked investments · listed companies and verified rows first
Acesion Pharma is a biotech company developing pharmaceutical treatments.
BiotechHealthtechMedical DevicesCopenhagen, DK
Ulrik Sørensen(COO & Co-founder)inMorten Grunnet(CSO & Co-founder)inAnders Gaarsdal Holst(CEO & CMO)inTorgeir Vaage(CFO)in
Co-investorsAlpha Wave GlobalCanaan PartnersNovo HoldingsBroadview Ventures
Altay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Ali Ozes(Founder)inOsman Ozes(Founder)inJAMES BREITMEYER(Executive Officer, Director)ERIC BJERKHOLT(Director)MIKE GREY(Director)ESTER SKLARSKY(Director)
Co-investorsCreative Destruction Lab (CDL)Fountain Healthcare PartnersHealthCapJude GomilaTachyon VenturesY Combinator+3 more
Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.
BiotechHealthtechLongevityPhiladelphia, US
Raj Kannan(Executive Officer, Director)
BoardClaudio Nessi(Director)inIvan Gergel(Director)inJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)
Co-investorsAndera PartnersAvego BioScience CapitalJeito CapitalKurma PartnersNew Rhein Healthcare Investors, LLCSeroba Life Sciences+2 more
Cartography develops antibody-based cancer therapies using single-cell sequencing and computational biology to identify precise cellular targets.
AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US
Max Mumbach(Founding Scientist, Target Discovery)inJeffrey Verboon(Founding Scientist, Computational Biology)inAnsu Satpathy(Founder)Kevin Parker, PhD(Chief Executive Officer, Board Director; co-founder)Ansuman Satpathy, MD, PhD(Co-founder; Board Director)Howard Chang(Founder)in
Co-investors8VCAndreessen HorowitzArtis VenturesCatalio Capital Management, LPFinchley Healthcare VenturesGaingels+9 more
__Twitter.png)
Ensho is a biopharmaceutical company developing NSHO-101, an oral, selective small molecule α4β7 inhibitor intended as a once-daily treatment for patients with inflammatory bowel disease (IBD).
BiotechHealthtechMorris Plains, US
Neena Bitritto-Garg(Founder)inGerhard Hagn(Chief Executive Officer)inDanielle Fry(Chief Operating Officer and Chief Legal Officer)inTory Trippe(Vice President, Head of Finance and Corporate Development)inMatthew R. Warr(Senior Vice President, Research & Head of Biology)inAndy Whitney(Chief Scientific Officer)in
Co-investorsAvego BioScience Capital
Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules.
BiotechHealthtech
Tim Wilson(Chief Executive Officer)Kevin FitzGerald(Chief Scientific Officer)inCristina Oliva(Chief Medical Officer)inNick Robbins-Cherry(Chief Financial Officer)inElizabeth Hardaker(Chief Translational Science Officer)
Co-investors3B Future Health FundAlbionVCBioGeneration VenturesEpidarex CapitalNovartis Venture FundUCL Technology Fund
Nuvig Therapeutics develops immune-modulating medicines for autoimmune diseases by harnessing endogenous regulatory mechanisms to resolve immune dysregulation.
BiotechHealthtechMedical Devices
Pamela Conley(Founder)in
Co-investorsB Capital GroupB4 CapitalMission BiocapitalSanofi VenturesDigitalis VenturesNorwest Venture Partners
.jpeg){kind=logo}
Nuvig Therapeutics is a biotech company developing immune-modulating therapies for autoimmune and chronic inflammatory diseases, using an endogenous regulatory mechanism intended to treat inflammation without compromising broader immune function.
BiotechLongevity
Co-investorsSanofi VenturesAlexandriaB CapitalDigitalis VenturesLeaps by BayerMission Biocapital+3 more
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)inGary D. Glick(Founder)Gary D. Glick, Ph.D.(Founder, President & CEO)
BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)
Co-investorsActivant CapitalAscenta CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGreatPoint Ventures+9 more
ShiraTronics is a medical device company developing an implantable device to treat chronic migraine disease.
BiotechHardwareHealthtechMedical DevicesBrooklyn Park, US
Robert Binney(Executive Officer, Director)
BoardJoyce Erony(Director)inZack Scott(Director)inBrad Vale(Director)inCasey Tansey(Director)Mudit Jain(Executive Officer, Director)in
Co-investorsAmzak HealthAPERTURE Venture PartnersBreakout VenturesNorwest Venture PartnersOSF VenturesSeroba Life Sciences+3 more
Vittoria develops immunotherapies, specifically CAR T-cell therapies, to treat difficult-to-treat diseases including cancers beyond B-cell types.
BiotechDeep TechMedical DevicesPhiladelphia, US
Nicholas Siciliano(Director)inPreston Noon(Executive Officer)
BoardGeeta Vemuri(Executive Officer, Director)Bruce Peacock(Executive Officer, Director)Leon Moulder(Director)
Co-investorsAgent CapitalBioAdvanceHatch BioFund
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.